Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2009
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts
Cathy Zhang, Zhengming Yan, Cory L Painter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2014
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib
Douglas D Fang, Bin Zhang, Qingyang Gu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth
Brion W Murray, Chuangxing Guo, Joseph Piraino, et al.
Journal of Hematology & Oncology
|
May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
NPJ Precision Oncology
|
August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Journal of Medicinal Chemistry
|
October 16, 2004
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase
Jayashree G Tikhe, Stephen E Webber, Zdenek Hostomsky, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition
Katherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Blood Advances
|
January 4, 2018
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
Shu-Hui Liu, Yin Gu, Bernadette Pascual, et al.
Journal of Medicinal Chemistry
|
November 1, 2002
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure
Stacie S Canan Koch, Lars H Thoresen, Jayashree G Tikhe, et al.
Journal of Medicinal Chemistry
|
June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Kevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2009
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts
Cathy Zhang, Zhengming Yan, Cory L Painter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2014
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib
Douglas D Fang, Bin Zhang, Qingyang Gu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 5, 2010
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth
Brion W Murray, Chuangxing Guo, Joseph Piraino, et al.
Journal of Hematology & Oncology
|
May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
NPJ Precision Oncology
|
August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Journal of Medicinal Chemistry
|
October 16, 2004
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase
Jayashree G Tikhe, Stephen E Webber, Zdenek Hostomsky, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition
Katherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Blood Advances
|
January 4, 2018
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
Shu-Hui Liu, Yin Gu, Bernadette Pascual, et al.
Journal of Medicinal Chemistry
|
November 1, 2002
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure
Stacie S Canan Koch, Lars H Thoresen, Jayashree G Tikhe, et al.
Journal of Medicinal Chemistry
|
June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Kevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Page
of 5